Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0583 • ACR Convergence 2023
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Miho Oyasu¹, Sivani Pandey¹, Maya Leabman¹, Genevive Hernandez¹, Albert Candia¹, Stephen Carroll¹, Bruce Keyt¹, Maya Kotturi¹, Carrie Brodmerkel² and Mary Beth Harler², ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
Abstract Number: 0600 • ACR Convergence 2023
Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline
Prathyusha Bachali¹, Amrie Grammer² and Peter Lipsky², ¹AMPEL BioSolutions, Redmond, WA, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Baricitinib is an inhibitor of Jak1 approved for treatment of rheumatoid arthritis, atopic dermatitis, alopecia areata and Covid-19. A phase 2 trial showed success…
Abstract Number: 0785 • ACR Convergence 2023
Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie M. Bartels³, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of lupus (or SLE) treatment. Yet the optimal dosing of HCQ in SLE is unknown. Reducing HCQ dose to…
Abstract Number: 0893 • ACR Convergence 2023
Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Annie Law¹, Chee Jian Pua², Dianyang Guo³, Chin Teck Ng⁴, Julian Thumboo¹, Andrea Hsiu Ling Low⁵ and Xiubo Fan¹, ¹Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²National Heart Centre, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1359 • ACR Convergence 2023
Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Lucy Masto¹, Amaya Smole¹, Caroline Siegel¹, Sarah Lieber², Sanjana Adurty³, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl², Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Weill Cornell Medical College, New York, NY
Background/Purpose: Whether the timing of menstruation impacts disease activity or severity among women with SLE or RA is poorly understood. We evaluated systemic rheumatic disease…
Abstract Number: 1455 • ACR Convergence 2023
Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus
Miyu Wakatsuki¹, Hiroyuki Yamashita¹, Yuuya Akiyama¹, Setsuko Oyama¹, Shintarou Aozaki¹, Ryo Kuwata², Misa Yamaji¹, Takuya Harada¹, Kyouko Motomura¹, Yuusuke Nakamichi¹ and Hiroshi Kaneko³, ¹National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan, ³Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan
Background/Purpose: Cytomegalovirus (CMV) infection is classified as an opportunistic infection that occurs in autoimmune diseases. Systemic lupus erythematosus (SLE) is one of the most frequently…
Abstract Number: 1472 • ACR Convergence 2023
Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience
Asif Hitawala¹, Zerai Manna², Yenealem Temesgen-Oyelakin³, Elaine Poncio³, Christopher Koh⁴, sarfaraz Hasni² and Theo Heller⁴, ¹NIDDK/NIH, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴NIDDK/Liver disease branch, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are known to have hepatic injury (HI), however large-scale longitudinal studies are lacking.We report our experience of HI…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1507 • ACR Convergence 2023
Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Chun Wu¹, Cristina Arriens², J. Michelle Kahlenberg³, Yanhua Hu¹, Coburn Hobar¹, Adrian Coles⁴ and Ian M. Catlett⁵, ¹Bristol Myers Squibb, Princeton, NJ, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³University of Michigan, Ann Arbor, MI, ⁴Bristol Myers Squibb, Lawrenceville, NJ, ⁵Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Deucravacitinib (DEUC) is a first-in-class, oral, selective, allosteric inhibitor of TYK2. TYK2 is required for signal transduction downstream of cytokines implicated in SLE pathophysiology,…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1834 • ACR Convergence 2023
Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort
Kelly Corbitt¹, Philip Carlucci², Brooke Cohen³, Mala Masson³, H Michael Belmont⁴, Amit Saxena⁵, Chung-E Tseng³, Jing Wang³, Kamil Barbour⁶, Jill Buyon⁷, Peter Izmirly² and Heather Gold³, ¹New York University, El Portal, FL, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, Rheumatology, New York, NY, ⁶Centers for Disease Control and Prevention, Atlanta, GA, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE patients have a higher prevalence of fibromyalgia (FM) than the general population. FM symptoms, such as nociplastic pain and fatigue, are known to…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].